Our roundup of the headlines for the week.
J&J to Resume Europe Vaccine Rollout
The European Medicines Agency has affirmed that the benefits of Johnson & Johnson's coronavirus vaccine, and its efficacy in preventing COVID-19, outweigh the risks associated with the jab. J&J followed up with a statement saying it would resume shipments to Europe, with updated labeling containing a warning about the rare yet serious side effect.
NICE Launches new 5-Year Strategy
The National Institute for Health and Care Excellence (NICE) has launched its strategy, with an aim of providing quicker access to new treatments and innovations, being more dynamic and collaborative in its work.
4 key pillars underpin the strategy for NICE's efforts:
- Leadership in data, research, and science
- Dynamic, living guideline recommendations
- Effective guidance uptake
- Rapid, robust, and responsive technology evaluation